Skip to main content

XENPOZYME Sanofi-Aventis Australia Pty Ltd

Product name
Accepted date
Active ingredients
olipudase alfa
Proposed indication
For the treatment of non-central
nervous system (CNS) manifestations of acid sphingomyelinase deficiency (ASMD).
Application type
A (new medicine)
Publication date

Registration process

Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.

Help us improve the Therapeutic Goods Administration site